Bosutinib (Bosulif) -

Bosutinib (Bosulif)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cancers
Summary
The SMC accepted bosutinib (Bosulif)for adults with chronic, accelerated & blast phase Philadelphia chromosome +ve chronic myelogenous leukaemia previously treated with ≥1 tyrosine kinase inhibitor(s) &for whom imatinib, nilotinib & dasatinib aren’t considered appropriate option.
UKMi comment
NICE does not recommend bosutinib for previously treated Philadelphia-chromosome-positive chronic myeloid leukaemia. However, the drug is available via the Cancer Drugs Fund for certain patients with chronic and accelerated phase Philadelphia chromosome +ve chronic myelogenous leukaemia. It is due to be removed from the list for
refractory blast crisis chronic myeloid leukaemia on 12 March 2015.
Related links: Link to NICE guidance (November 2013)Link to CDF list (January 2015)